美国斯克里普斯研究所2024年招聘博士后职位（病毒病原体疫苗开发）

斯克利普斯研究所（Scripps Research，旧称The Scripps Research Institute，缩写为TSRI）是一所私立的非营利性的生物医学研究机构，成立于1924年。斯克里普斯研究学院是美国同类机构中最大的。斯克里普斯研究所基础研究含盖免疫学，分子和细胞生物学，化学，神经科学，自身免疫性疾病，心血管病学，病毒学和合成疫苗的发展。TSRI在这些学科领域的研究均获得国际上的公认，其中以在生物分子的基本机构和设计方式的研究方面表现尤为突出，是少数几个世界领先的中心之一。根据美国新闻与世界报道在2007年进行的排名，斯克里普斯研究学院在美国最好的生物科学研究院中排名第7位，在最好的化学研究院中排名第6位。

Postdoctoral Associate – Zhu Lab

Scripps Research

Postdoctoral positions are available in Dr. Jiang Zhu's laboratory for highly motivated candidates who are interested in vaccine development for viral pathogens such as HIV-1, HCV, Flu, SARS-CoV-1/2, MERS-CoV, Ebola/Marburg, RSV/hMPV, and ZIKV. Salary is in the range of $68,000 to $78,000, depending on prior experience and qualifications. Dr. Zhu holds a joint appointment in the Department of Integrative Structural and Computational Biology (ISCB) and the Department of Immunology and Microbiology at Scripps Research in La Jolla, CA (www.scripps.edu). Dr. Zhu's laboratory combines structure-based antigen design, protein nanoparticle engineering, animal immunization, single-cell technologies, and immunological assays to develop and evaluate next-generation vaccines. Multiple vaccine candidates are currently under clinical development with ongoing and planned phase-I human trials. Details of Dr. Zhu's laboratory, ongoing research projects, and recent publications can be found at www.jzhulab.org. Dr. Zhu is also the co-founder of Uvax Bio LLC (www.uvaxbio.com), a vaccine biotechnology company that aims to address global health challenges with innovative vaccine solutions. An HIV-1 nanoparticle vaccine candidate developed by the Zhu lab is currently in the Phase 1 clinical trial in Australia (ANZCTR registration #: ACTRN12624000064505), which is sponsored by Uvax Bio. An NIH-sponsored Phase 1 clinical trial is under preparation and is expected to take place in early 2025.

Research projects for this postdoctoral position will focus on the study of vaccine-induced adaptive immune responses and involve the use of single-cell technologies, such as antigen-specific single B-cell sorting by flow cytometry and single-cell immune profiling using 10X Chromium, antibody cloning and synthesis, and next-generation sequencing (NGS) of B-cell repertoires.

Successful candidates will have a recent Ph.D. in molecular biology, immunology, or other related fields. Candidates with prior experience and strong expertise in single-cell antibody technologies are especially encouraged to apply.

Interested applicants should send the following materials, preferably as a single PDF file, by email to Dr. Jiang Zhu (jiang@scripps.edu):

Cover letter indicating current and future research interests

Expected starting date

Curriculum vitae

Brief summary of previous research experience (2-3 pages)

Names and contact information for 3 references.

The above statements describe the level of work performed and expected in general terms. The statements are not intended to list all the responsibilities, duties, and/or skills required of employees so classified, and the content herein is subject to change due to the business needs of Scripps Research, with or without notice. Furthermore, nothing in this job description shall be interpreted to be in conflict with or to eliminate or modify in any way the employment-at-will status of Scripps Research staff.

EEO Statement:The Scripps Research Institute is an Equal Opportunity Employer. We promote diversity of thought, culture, and background in the fields of science. All qualified applicants are encouraged to apply and will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability, protected veteran status, or any other legally protected characteristic or status. Underrepresented individuals are encouraged to apply.